{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:24:38Z","timestamp":1787030678371,"version":"build-2736575974"},"reference-count":25,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2024]]},"DOI":"10.3960\/jslrt.24021","type":"journal-article","created":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T18:12:22Z","timestamp":1722363142000},"page":"191-202","source":"Crossref","is-referenced-by-count":3,"title":["Real-world retrospective analysis of immune checkpoint inhibitor therapy for relapsed or refractory Hodgkin\u2019s lymphoma"],"prefix":"10.3960","volume":"64","author":[{"given":"Tatsuo","family":"Oyake","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Iwate Medical University School of Medicine, Yahaba, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Maeta","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Iwate Medical University School of Medicine, Yahaba, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takenori","family":"Takahata","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hematology and Clinical Immunology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiko","family":"Tamai","sequence":"additional","affiliation":[{"name":"Department of Transfusion and Cell Therapy Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Kameoka","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuro","family":"Miyairi","sequence":"additional","affiliation":[{"name":"Division of Hematology, Iwate Prefectural Central Hospital, Morioka, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Murai","sequence":"additional","affiliation":[{"name":"Division of Hematology, Iwate Prefectural Central Hospital, Morioka, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Shimosegawa","sequence":"additional","affiliation":[{"name":"Division of Hematology, Iwate Prefectural Chubu Hospital, Kitakami, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kozue","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Division of Hematology, Iwate Prefectural Isawa Hospital, Oshu, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Inokura","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tohoku University Graduate School of Medicine, Sendai, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Fukuhara","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tohoku University Graduate School of Medicine, Sendai, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Harigae","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tohoku University Graduate School of Medicine, Sendai, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Sato","sequence":"additional","affiliation":[{"name":"Division of Hematology and Cell Therapy, Department of Third Internal Medicine, Yamagata University Faculty of Medicine, Yamagata, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Ishizawa","sequence":"additional","affiliation":[{"name":"Division of Hematology and Cell Therapy, Department of Third Internal Medicine, Yamagata University Faculty of Medicine, Yamagata, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsushi","family":"Tajima","sequence":"additional","affiliation":[{"name":"Department of Hematology, Yamagata Prefectural Central Hospital, Yamagata, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souichi","family":"Saitou","sequence":"additional","affiliation":[{"name":"Division of Hematology, Nihonkai General Hospital, Sakata, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Fukatsu","sequence":"additional","affiliation":[{"name":"Department of\u00a0Hematology, Fukushima Medical University, Fukushima, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Ikezoe","sequence":"additional","affiliation":[{"name":"Department of\u00a0Hematology, Fukushima Medical University, Fukushima, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saburo","family":"Tsunoda","sequence":"additional","affiliation":[{"name":"Department of Hematology, Aizu Medical Center Fukushima Medical University, Aizuwakamatsu, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Mita","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, Shirakawa Kosei General Hospital, Shirakawa, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinichi","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Hematology, Joban Hospital, Tokiwa Foundation, Iwaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shugo","family":"Kowata","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Iwate Medical University School of Medicine, Yahaba, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Ito","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, Iwate Medical University School of Medicine, Yahaba, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Bray F, Ferlay J, Soerjomataram I <i>et al.<\/i> Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68: 394-424.","DOI":"10.3322\/caac.21492"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 . The world health organization classification of malignant lymphomas in japan: incidence of recently recognized entities. Pathol Int. 2000; 50: 696-702.","DOI":"10.1046\/j.1440-1827.2000.01108.x"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Nagai H. JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-10. Hodgkin lymphoma (HL). Int J Hematol. 2020; 111: 166-179.","DOI":"10.1007\/s12185-019-02785-w"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Connors JM, Jurczak W, Straus DJ <i>et al.<\/i> Brentuximab vedotin with chemotherapy for Stage III or IV Hodgkin\u2019s lymphoma. N Engl J Med. 2018; 378: 331-344.","DOI":"10.1056\/NEJMoa1708984"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Straus DJ, D\u0142ugosz-Danecka M, Connors JM <i>et al.<\/i> Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Lancet Haematol. 2021; 8: e410-e421.","DOI":"10.1016\/S2352-3026(21)00102-2"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Schmitz N, Pfistner B, Sextro M <i>et al.<\/i> Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomised trial. Lancet. 2002; 359: 2065-2071.","DOI":"10.1016\/S0140-6736(02)08938-9"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Linch DC, Winfield D, Goldstone AH <i>et al.<\/i> Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin\u2019s disease: results of a BNLI randomised trial. Lancet. 1993; 341: 1051-1054.","DOI":"10.1016\/0140-6736(93)92411-L"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Yuen AR, Rosenberg SA, Hoppe RT, Halpern JD, Horning SJ. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin\u2019s disease. Blood. 1997; 89: 814-822.","DOI":"10.1182\/blood.V89.3.814"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Ansell SM, Lesokhin AM, Borrello I <i>et al.<\/i> PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med. 2015; 372: 311-319.","DOI":"10.1056\/NEJMoa1411087"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Younes A, Santoro A, Shipp M <i>et al.<\/i> Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016; 17: 1283-1294.","DOI":"10.1016\/S1470-2045(16)30167-X"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Chen R, Zinzani PL, Fanale MA <i>et al.<\/i> Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma. J Clin Oncol. 2017; 35: 2125-2132.","DOI":"10.1200\/JCO.2016.72.1316"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Maruyama D, Hatake K, Kinoshita T <i>et al.<\/i> Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma. Cancer Sci. 2017; 108: 1007-1012.","DOI":"10.1111\/cas.13230"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Maruyama D, Terui Y, Yamamoto K <i>et al.<\/i> Final results of a phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma. Jpn J Clin Oncol. 2020; 50: 1265-1273.","DOI":"10.1093\/jjco\/hyaa117"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Chen R, Zinzani PL, Lee HJ <i>et al.<\/i> Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood. 2019; 134: 1144-1153.","DOI":"10.1182\/blood.2019000324"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Makita S, Maruyama D, Maeshima AM <i>et al.<\/i> Clinical features and outcomes of 139 Japanese patients with Hodgkin lymphoma. Int J Hematol. 2016; 104: 236-244.","DOI":"10.1007\/s12185-016-2007-1"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Ogura M, Itoh K, Kinoshita T <i>et al.<\/i> Phase II study of ABVd therapy for newly diagnosed clinical stage II-IV Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG 9305). Int J Hematol. 2010; 92: 713-724.","DOI":"10.1007\/s12185-010-0712-8"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Cheson BD, Pfistner B, Juweid ME <i>et al.<\/i> Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25: 579-586.","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013; 48: 452-458.","DOI":"10.1038\/bmt.2012.244"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Sirohi B, Cunningham D, Powles R <i>et al.<\/i> Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin\u2019s lymphoma. Ann Oncol. 2008; 19: 1312-1319.","DOI":"10.1093\/annonc\/mdn052"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Bekoz H, Ozbalak M, Karadurmus N <i>et al.<\/i> Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience. Ann Hematol. 2020; 99: 2565-2576.","DOI":"10.1007\/s00277-020-04077-4"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Gaudio F, Loseto G, Bozzoli V <i>et al.<\/i> A real-world analysis of PD1 blockade from the Rete Ematologica Pugliese (REP) in patients with relapse\/refractory Hodgkin\u2019s lymphoma. Ann Hematol. 2023; 102: 385-392.","DOI":"10.1007\/s00277-023-05100-0"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Bair SM, Strelec LE, Feldman TA <i>et al.<\/i> Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis. Oncologist. 2019; 24: 955-962.","DOI":"10.1634\/theoncologist.2018-0538"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Armand P, Engert A, Younes A <i>et al.<\/i> Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm Phase II CheckMate 205 trial. J Clin Oncol. 2018; 36: 1428-1439.","DOI":"10.1200\/JCO.2017.76.0793"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Ansell SM, Br\u00f6ckelmann PJ, von Keudell G <i>et al.<\/i> Nivolumab for relapsed\/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study. Blood Adv. 2023; 7: 6266-6274.","DOI":"10.1182\/bloodadvances.2023010334"},{"key":"25","unstructured":"25 Thompson JA, Schneider BJ, Brahmer J <i>et al.<\/i> NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. J Natl Compr Canc Netw. 2020; 18: 230-241."}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/64\/3\/64_24021\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T01:06:12Z","timestamp":1727485572000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/64\/3\/64_24021\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.24021","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"article-number":"24021"}}